公开(公告)号：US10933122B2

公开(公告)日：2021-03-02

申请号：US16521622

申请日：2019-07-25

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Irit Sagi ,  Eitan Wong ,  Ran Afik

IPC: C12N9/64 ,  A61K38/48

Abstract: A method of treating an inflammatory disease is disclosed. The method comprises administering to the subject a therapeutically effective amount of a polypeptide comprising a pro-domain of TNF-alpha converting enzyme (TACE), said polypeptide being devoid of a catalytic domain of said TACE, said polypeptide comprising a modification at a site selected from the group consisting of R58, R56 and K57 which renders said polypeptide resistant to furin degradation said polypeptide being capable of downregulating an activity of TACE, thereby treating the inflammatory disease.

公开(公告)号：US10426821B2

公开(公告)日：2019-10-01

申请号：US15636683

申请日：2017-06-29

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Irit Sagi ,  Eitan Wong ,  Ran Afik

IPC: C12N9/64 ,  A61K38/48

Abstract: A method of treating an inflammatory disease is disclosed. The method comprises administering to the subject a therapeutically effective amount of a polypeptide comprising a pro-domain of TNF-alpha converting enzyme (TACE), said polypeptide being devoid of a catalytic domain of said TACE, said polypeptide comprising a modification at a site selected from the group consisting of R58, R56 and K57 which renders said polypeptide resistant to furin degradation said polypeptide being capable of downregulating an activity of TACE, thereby treating the inflammatory disease.

公开(公告)号：US08999332B2

公开(公告)日：2015-04-07

申请号：US13916633

申请日：2013-06-13

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Irit Sagi ,  Gabriel Rosenblum

IPC: A61K39/395 ,  C12N9/64 ,  A61K38/00

CPC classification number: C07K16/40 ,  A61K38/005 ,  A61K39/3955 ,  C07K2299/00 ,  C12N9/6491 ,  C12Q1/37 ,  C12Y304/24035 ,  G01N33/573 ,  G01N2333/96494 ,  G01N2500/04 ,  G01N2500/20

Abstract: A method of regulating an activity of metalloproteinase 9 (MMP-9) is disclosed. The method comprises contacting the MMP-9 with an agent which specifically interacts with an OG domain of the MMP-9. Molecules capable of specifically interacting with the OG domain, methods of identifying same, pharmaceutical compositions comprising same and uses thereof are also disclosed.

Abstract translation: 公开了一种调节金属蛋白酶9（MMP-9）活性的方法。 该方法包括使MMP-9与与MMP-9的OG结构域特异性相互作用的试剂接触。 还可以公开能够与OG结构域特异性相互作用的分子，鉴定其的方法，包含其的药物组合物及其用途。

公开(公告)号：US12291578B2

公开(公告)日：2025-05-06

申请号：US17429672

申请日：2020-02-10

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Irit Sagi ,  Vishnu Mohan

IPC: C07K16/40 ,  A61K31/282 ,  A61K31/7068 ,  A61K39/00 ,  A61P35/00 ,  C07K16/30

Abstract: A method of treating a disease associated with imbalanced or abnormal activity of MMP-7 is diclosed. The method comprises administration of an antibody comprising an antigen recognition region which binds a catalytic site of MMP-7, having complementarity determining region amino acid sequences as set forth in: SEQ ID NOs: 3, 4 and 5 (CDR3), sequentially arranged from N to C on a light chain of the antibody; and SEQ ID NOs: 6, 7 and 8, sequentially arranged from N to C on a heavy chain of the antibody.

公开(公告)号：US09902783B2

公开(公告)日：2018-02-27

申请号：US15161375

申请日：2016-05-23

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Irit Sagi ,  Tamar Danon ,  Netta Sela ,  Abraham Shanzer ,  Rina Arad-Yellin ,  Raghavendra Kikkeri

IPC: C07K16/44 ,  C07F3/06 ,  C07D233/61 ,  C07K16/40

CPC classification number: C07K16/44 ,  C07D233/61 ,  C07F3/06 ,  C07K16/40 ,  C07K2317/565 ,  C07K2317/76

Abstract: An antibody comprising an antigen recognition region which comprises CDR amino acid sequences set forth in SEQ ID NO: 7, 8, 9, 10, 11 and 12.

公开(公告)号：US09764008B2

公开(公告)日：2017-09-19

申请号：US14398754

申请日：2013-05-09

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Irit Sagi ,  Eitan Wong ,  Ran Afik

IPC: A61K38/54 ,  A61K38/48 ,  C12N9/64

CPC classification number: A61K38/4886 ,  C12N9/6489 ,  C12Y304/24086 ,  Y02A50/473

Abstract: A method of treating an inflammatory disease is disclosed. The method comprises administering to the subject a therapeutically effective amount of a polypeptide comprising a pro-domain of TNF-alpha converting enzyme (TACE), said polypeptide being devoid of a catalytic domain of said TACE, said polypeptide comprising a modification at a site selected from the group consisting of R58, R56 and K57 which renders said polypeptide resistant to furin degradation said polypeptide being capable of downregulating an activity of TACE, thereby treating the inflammatory disease.

公开(公告)号：US20150132281A1

公开(公告)日：2015-05-14

申请号：US14398754

申请日：2013-05-09

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Irit Sagi ,  Eitan Wong ,  Ran Afik

IPC: A61K38/48 ,  C12N9/64

CPC classification number: A61K38/4886 ,  C12N9/6489 ,  C12Y304/24086 ,  Y02A50/473

Abstract: A method of treating an inflammatory disease is disclosed. The method comprises administering to the subject a therapeutically effective amount of a polypeptide comprising a pro-domain of TNF-alpha converting enzyme (TACE), said polypeptide being devoid of a catalytic domain of said TACE, said polypeptide comprising a modification at a site selected from the group consisting of R58, R56 and K57 which renders said polypeptide resistant to furin degradation said polypeptide being capable of downregulating an activity of TACE, thereby treating the inflammatory disease.

Abstract translation: 公开了一种治疗炎性疾病的方法。 该方法包括向受试者施用治疗有效量的包含TNF-α转换酶（TACE）的前域的多肽，所述多肽缺乏所述TACE的催化结构域，所述多肽在所选择的位点包含修饰 来自由R58，R56和K57组成的组，其使所述多肽对弗林蛋白酶降解具有抗性，所述多肽能够下调TACE的活性，从而治疗炎性疾病。

公开(公告)号：US10040868B2

公开(公告)日：2018-08-07

申请号：US15328036

申请日：2014-07-24

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Irit Sagi ,  Moran Grossman ,  Nir Ben-Chetrit

IPC: A61K39/00 ,  A61K39/395 ,  C07K16/40 ,  A61K45/06 ,  A61K33/24

Abstract: An article of manufacture is disclosed which comprises at least two active agents, wherein a first of the two active agents comprises an anti-cancer agent or an antifibrotic agent and a second of the at least two active agents downregulates the activity and/or expression of lysyl-oxidase like protein-2 (LOXL-2) and which is capable of altering the structure of the extracellular matrix.

公开(公告)号：US09416195B2

公开(公告)日：2016-08-16

申请号：US13872265

申请日：2013-04-29

Applicant: Yeda Research and Development Co., Ltd.

Inventor： Irit Sagi ,  Tamar Danon ,  Netta Sela ,  Abraham Shanzer ,  Rina Arad-Yellin ,  Raghavendra Kikkeri

IPC: C07K16/44 ,  C07F3/06 ,  C07D233/61 ,  C07K16/40

CPC classification number: C07K16/44 ,  C07D233/61 ,  C07F3/06 ,  C07K16/40 ,  C07K2317/565 ,  C07K2317/76

Abstract: An antibody comprising an antigen recognition region which comprises CDR amino acid sequences set forth in SEQ ID NO: 7, 8, 9, 10, 11 and 12.

公开(公告)号：US09217041B2

公开(公告)日：2015-12-22

申请号：US14168024

申请日：2014-01-30

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Irit Sagi ,  Netta Sela-Paswell ,  Tamar Danon ,  Raanan Margalit

IPC: A61K39/395 ,  A61K39/00 ,  C07K16/40 ,  C07K16/44

CPC classification number: C07K16/40 ,  A61K2039/505 ,  C07K16/44 ,  C07K2317/55 ,  C07K2317/76 ,  C07K2317/92

Abstract: An antibody is disclosed which comprises an antigen recognition region which comprises six CDR amino acid sequences selected from the group consisting of SEQ ID NOs: 4-15. Uses thereof are also disclosed.

Abstract translation: 公开了包含抗原识别区的抗体，其包含选自SEQ ID NO：4-15的6个CDR氨基酸序列。 还公开了其用途。